Reaffirms Continuation of Evaluation of Strategic Alternatives SAN DIEGO / Nov 12, 2024 / Business Wire / MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its quarter ended September 30, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. In the review, the Company continues to consider options such as out-licensing... Read More

Confirms Continuation of Evaluation of Strategic Alternatives SAN DIEGO / Sep 19, 2024 / Business Wire / MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its fiscal year ended June 30, 2024. Previously on July 22, 2024, the Company announced the commencement of an evaluation of strategic alternatives with the goal of maximizing the value of its assets for its stockholders. Subsequent to that date,... Read More

SAN DIEGO / Aug 12, 2024 / Business Wire / MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today announced that it has engaged Oppenheimer & Co. Inc. to serve as the Company’s exclusive financial advisor to assist in its previously announced process to review and evaluate strategic alternatives. The Company remains focused on maximizing the value of its assets for its stockholders. There can be no assurance the exploration... Read More

Company Commences a Cash Preservation Plan Including a Reduction in Force SAN DIEGO / Jul 22, 2024 / Business Wire / MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today announced that its Board of Directors has determined unanimously to begin evaluation of the Company’s strategic alternatives, including potential transactions as well as an orderly wind down of the Company, if appropriate, in order to maximize the value of... Read More

Ongoing Phase 1 Study Evaluating Voruciclib Plus Venetoclax Demonstrates Anti-leukemic Activity, Including Complete Responses, Anticipated Decreases in Mcl-1 and No Overlapping Toxicity in Heavily Pretreated R/R AML Patients Board of Directors Unanimously Aligned on Prioritization of Voruciclib Program Development MEI Begins Fourth Fiscal Quarter with $56.6 Million in Cash SAN DIEGO / May 09, 2024 / Business Wire / MEI... Read More

Cohort 1 Exceeds Predetermined Non-Progression Threshold in the Ongoing Phase 1b Study ME-344 in Combination with Bevacizumab was Generally Well-tolerated with no Evidence of Overlapping Toxicity MEI to Continue Advancing ME-344 via Development of a New Formulation with the Potential to Increase Biological Activity, Patient Convenience and Commercial Opportunity SAN DIEGO / Apr 11, 2024 / Business Wire / MEI Pharma, Inc.... Read More

MEI Pharma Board Unanimously Determines, Based on Clinical Data Results, Not to Proceed with Second Capital Return Under 2023 Anson and Cable Car Cooperation Agreement: Conserving Capital, Prioritizing Measured Investment, Extending Operational Runway SAN DIEGO / Apr 11, 2024 / Business Wire / MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance... Read More

SAN DIEGO / Apr 10, 2024 / Business Wire / MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced that David Urso, president and chief executive officer of MEI Pharma, will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Tuesday, April 16 at 1:30... Read More

Enrollment Initiated in 12-Patient Expansion Cohort Evaluating Voruciclib Plus Venetoclax in Ongoing Phase 1 Study Anti-leukemic Activity Across Multiple Heavily Pretreated Patients Demonstrated Along with Anticipated Decreases in Mcl-1 No Evidence of Overlapping Toxicity, and No Dose Limiting Toxicities Observed to Date in Dose Escalation Cohorts SAN DIEGO / Mar 26, 2024 / Business Wire / MEI Pharma, Inc. (Nasdaq: MEIP), a... Read More

SAN DIEGO / Feb 13, 2024 / Business Wire / MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the three and six months ended December 31, 2023, and highlighted recent corporate events. “In the ongoing clinical studies for both voruciclib, our oral CDK9 inhibitor, and... Read More

Ongoing Phase 1b Study Evaluating ME-344 Plus Avastin® in Patients with Metastatic Colorectal Cancer: Combination Intended to Create Metabolic Synthetic Lethality SAN DIEGO / Jan 16, 2024 / Business Wire / MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced the design of the... Read More

Safety Profile Observed to Date as Monotherapy and in Combination with Venetoclax Suggests no Overlapping Toxicity Initial Results from Correlative Studies Demonstrate On-target Reductions in Mcl-1 and RNA Pol II p-S2 SAN DIEGO / Dec 11, 2023 / Business Wire / MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care... Read More

SAN DIEGO / Nov 09, 2023 / Business Wire / MEI Pharma, Inc . (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the quarter ended September 30, 2023 and highlighted recent corporate events. “Our ongoing clinical studies evaluating the combination of voruciclib, our CDK9 inhibitor, with... Read More

SAN DIEGO / Nov 08, 2023 / Business Wire / MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced it will participate in the Stifel 2023 Healthcare Conference. David Urso, president and chief executive officer, will present a company overview and business update on Wednesday, November 15 at 8:35 AM Eastern Time. Investors and the general public... Read More

SAN DIEGO / Nov 06, 2023 / Business Wire / MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that pursuant to the previously disclosed cooperation agreement with Anson Funds and Cable Car Capital, the Company’s Board of Directors today declared a special cash dividend (the “Dividend”) of $1.75 per share of common stock,... Read More

SAN DIEGO / Nov 02, 2023 / Business Wire / MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that an abstract highlighting clinical data from the monotherapy dose escalation stage of the ongoing Phase 1 study evaluating voruciclib, a selective oral cyclin-dependent kinase 9 (CDK9) inhibitor, alone and in combination with venetoclax... Read More

Commits to Capital Return of Up to $3.15 per Share Adds Three New Directors and Forms Capital Allocation Committee of the Board SAN DIEGO & TORONTO & SAN FRANCISCO / Nov 01, 2023 / Business Wire / MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) and Anson Funds and Cable Car Capital (“Anson and Cable Car”) today announced that they have entered into a cooperation agreement. Key terms of the agreement include: Capital Return... Read More

Files Definitive Consent Revocation Statement Mails Letter to Stockholders Highlighting the Path to Realizing the Full Value of Their MEI Investment Urges Stockholders Not to be Misled by Anson Advisors and Cable Car Capital and Not to Consent to Their Agenda SAN DIEGO / Oct 17, 2023 / Business Wire / MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today announced that it has filed a definitive consent revocation statement... Read More

Responds to Substantial Stock Accumulation by Anson Advisors and Cable Car Capital Protects Long-Term Value of All Stockholders’ Investments in MEI Pharma SAN DIEGO / Oct 02, 2023 / Business Wire / MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that its Board of Directors has unanimously approved the adoption of a limited-duration... Read More

SAN DIEGO / Sep 28, 2023 / Business Wire / MEI Pharma, Inc. (Nasdaq: MEIP) (the “MEI” or “the Company”) today issued the following statement in response to the consent solicitation initiated by a group led by Anson Advisors Inc. and Cable Car Capital LLC. The MEI Board of Directors and management team are focused on advancing our two programs, voruciclib and ME-344, both on the cusp of reporting clinical data during the... Read More

Conference Call Today at 5:00 p.m. Eastern Time SAN DIEGO / Sep 26, 2023 / Business Wire / MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended June 30, 2023. "Over just the next few quarters we look forward to data readouts from two ongoing clinical studies of voruciclib and ME-344, advancing our strategy of... Read More

SAN DIEGO / Sep 21, 2023 / Business Wire / MEI Pharma, Inc. (NASDAQ: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Company will release its 2023 fiscal year end financial results after the close of the U.S. financial markets on September 26, 2023. Company management will host a conference call and webcast that day at 5:00 p.m. ET to discuss the results... Read More

No Stockholder Action Required at This Time SAN DIEGO / Sep 18, 2023 / Business Wire / MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today issued the following statement regarding the nomination of three director candidates by Anson Advisors Inc. and Cable Car Capital LLC to stand for election to the Company’s Board of Directors at MEI’s fiscal year 2024 Annual Meeting of Stockholders. MEI, a clinical development company... Read More

SAN DIEGO / Aug 16, 2023 / Business Wire / MEI Pharma, Inc. (NASDAQ: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the dosing of the first patient in a Phase 1b study evaluating ME-344 in combination with bevacizumab (AVASTIN®) in patients with previously treated metastatic colorectal cancer. ME-344 is a novel mitochondrial inhibitor targeting energy production... Read More

SAN DIEGO / Jul 23, 2023 / Business Wire / MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today announced that, based on a count of the votes cast at the Company’s Special Meeting of Stockholders, MEI, by a narrow margin, did not obtain the necessary stockholder votes to approve the merger agreement with Infinity Pharmaceuticals, Inc. (“Infinity”). The certified results show that 59.70% of outstanding shares were voted, of... Read More

SAN DIEGO / Jul 19, 2023 / Business Wire / MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today reminded shareholders to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) in connection with the Company’s special meeting on July 23, 2023. MEI issued the following statement: Our shareholders have the opportunity to shape the future of their MEI investment. By voting FOR the... Read More

SAN DIEGO / Jul 18, 2023 / Business Wire / MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today issued the following statement in response to the Consent Solicitation launched by Anson Advisors Inc. and Cable Car Capital LLC on July 17, 2023: Anson and Cable Car have launched a process, called a consent solicitation, in an attempt to take control of the Company by removing MEI’s directors. The consent solicitation further... Read More

Believe the Board Needs to be Held Accountable for its Poor Judgment and Value-Destructive Initiatives Reiterate their Concern that the Board is Not Acting in the Best Interest of Stockholders Believe Immediate Action Must be Taken to Prevent the Further Destruction of Value TORONTO and SAN FRANCISCO, July 17, 2023 (GLOBE NEWSWIRE) -- Anson Funds (“Anson”) and Cable Car Capital LLC (“Cable Car” and, together with Anson, “we”... Read More

SAN DIEGO / Jul 17, 2023 / Business Wire / MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today mailed the following letter to shareholders, encouraging them to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) in connection with the Company’s special meeting on July 23, 2023, at 10:00 a.m. Eastern Time: Dear Fellow MEI Shareholders, We have extended the opportunity for... Read More

SAN DIEGO / Jul 13, 2023 / Business Wire / MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today announced that it has postponed its special meeting in connection with the proposed transaction with Infinity Pharmaceuticals, Inc. (“Infinity”) to July 23, 2023, at 10:00 a.m. Eastern Time, unless postponed or adjourned to a later date. MEI issued the following statement: With the postponement of the special meeting, MEI... Read More

SAN DIEGO / Jul 11, 2023 / Business Wire / MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today reminded shareholders to vote FOR the Company’s pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) in connection with the upcoming special meeting on July 14, 2023. MEI issued the following statement: With the special meeting just days away, now is the time for MEI shareholders to vote FOR our... Read More

Glass Lewis Joins ISS in Recommending that MEI Shareholders Vote FOR the Infinity Transaction SAN DIEGO / Jul 07, 2023 / Business Wire / MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today reminded shareholders to vote FOR the Company’s pending transaction with Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”) in connection with the upcoming special meeting on July 14, 2023. The Company noted that leading proxy... Read More

Affirms Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals Highlights Shareholder Opportunity to Participate in Upside Potential of Diversified Combined Pipeline of Three Clinical-Stage Development Programs SAN DIEGO / Jul 05, 2023 / Business Wire / MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today announced that leading independent proxy advisory firm Institutional Shareholder Services... Read More

Highlights Shareholder Opportunity to Participate in Upside Potential of Diversified Combined Pipeline of Three Clinical-Stage Development Programs Combined Company Well-Positioned to Make a Difference in Cancer Care With Significant Potential to Deliver Improved Therapeutic Options for Patients Board Reiterates Recommendation to Shareholders to Vote FOR the Merger Agreement with Infinity Pharmaceuticals Ahead of the Special... Read More

SAN DIEGO / Jun 27, 2023 / Business Wire / MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today issued the following statement in response to the disclosure made today by Anson Advisors Inc. and Cable Car Capital LLC: Anson and Cable Car reiterated their formerly disclosed, unsolicited and non-binding proposal that our Board of Directors previously reviewed and rejected. The Board determined that the proposal provides no... Read More

Emphasizes the Board’s Failure to Adequately Consider the Superior Acquisition Proposal Presented by Anson Funds and Cable Car Capital Believes the Misguided Transaction with Infinity Pharmaceuticals Will Continue to Destroy Stockholder Value Have Voted Against the Proposed Combination ahead of the Upcoming Special Meeting Scheduled for July 14, 2023 TORONTO and SAN FRANCISCO, June 27, 2023 (GLOBE NEWSWIRE) -- Anson Funds... Read More

Event Available at 8:00 a.m. Eastern Time on June 19, 2023 SAN DIEGO & CAMBRIDGE, Mass. / Jun 15, 2023 / Business Wire / MEI Pharma, Inc. (Nasdaq: MEIP) (“MEI”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage... Read More

SAN DIEGO / Jun 13, 2023 / Business Wire / MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that, consistent with the Company’s succession planning, Brian Drazba’s tenure as Chief Financial Officer of the Company will end no later than September 1, 2023, and the Company has hired Justin (Jay) File as his successor. Mr. File... Read More

SAN DIEGO / Jun 02, 2023 / Business Wire / MEI Pharma, Inc. ( NASDAQ: MEIP) (the “Company”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that, in connection with the Company’s previously announced succession plan, Daniel P. Gold, Ph.D’s tenure as the president and chief executive officer of MEI will end on June 2, 2023 and the Company’s board of directors has... Read More

TORONTO and SAN FRANCISCO, June 01, 2023 (GLOBE NEWSWIRE) -- Anson Funds (“Anson”) and Cable Car Capital LLC (“Cable Car” and, together with Anson, “we” or “us”), which collectively beneficially own approximately 14.8% of the outstanding common stock of MEI Pharma, Inc. (the “Company” or “MEIP”; NasdaqCM: MEIP), today issued the following statement in response to the rejection by the Company’s board of directors (the... Read More

SAN DIEGO / Jun 01, 2023 / Business Wire / MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today announced that its Board of Directors (the “Board”) reviewed and rejected the unsolicited and non-binding proposal received on May 23, 2023 from a group represented by Anson Advisors Inc. and Cable Car Capital LLC to acquire all outstanding shares of MEI for not less than $8.00 in cash per share, plus a contingent value right... Read More

SAN DIEGO / May 30, 2023 / Business Wire / MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today confirmed receipt of an unsolicited and non-binding proposal on May 23, 2023 from a group represented by Anson Advisors Inc. and Cable Car Capital LLC, as referenced in their 13-D filing of earlier today, to acquire all outstanding shares of MEI for not less than $8.00 in cash per share, plus a contingent value right representing... Read More

Voruciclib alone or in combination with venetoclax was generally well tolerated with no significant myelosuppression Encouraging preliminary efficacy signal demonstrated with voruciclib alone and at the first dose level with voruciclib in combination with venetoclax SAN DIEGO / May 23, 2023 / Business Wire / MEI Pharma, Inc. (NASDAQ: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for... Read More

MEI Begins Fourth Fiscal Quarter with $112.0 Million in Cash SAN DIEGO / May 11, 2023 / Business Wire / MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended March 31, 2023, and highlighted recent corporate events. “We are making steady progress in advancing both of our clinical-stage pipeline programs: voruciclib... Read More

SAN DIEGO / Apr 14, 2023 / Business Wire / MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that its board of directors approved a 1-for-20 reverse stock split. The Company’s common stock will open for trading on the Nasdaq Capital Market on Monday, April 17, 2023 on a split-adjusted basis under the current trading symbol "MEIP." The... Read More

SAN DIEGO / Feb 09, 2023 / Business Wire / MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended December 31, 2022, and highlighted recent corporate events. “MEI anticipates reporting key clinical data readouts on two clinical-stage oncology candidates, voruciclib and ME-344, around the end of the calendar year for... Read More

Company continuing development efforts on its two early clinical-stage oncology assets: voruciclib and ME-344 MEI expects existing cash sufficient to fund through clinical data milestones for voruciclib and ME-344 SAN DIEGO--( BUSINESS WIRE )-- MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that it plans to initiate a realignment of its... Read More

SAN DIEGO & TOKYO--( BUSINESS WIRE )-- MEI Pharma, Inc. (Nasdaq: MEIP), a pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a Japan-based global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that after receiving the most recent guidance from a late November meeting with the U.S.... Read More

Interim data from Phase II Study of Zandelisib shows 75.4% ORR in Japanese patients with Indolent B-cell NHL Publication of results from additional Phase 1 study now available in International Journal of Hematology TOKYO & SAN DIEGO--(BUSINESS WIRE)-- Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology and MEI... Read More